Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net revenues:
Total net revenues	$ 3,095	$ 1,724	$ 7,173	$ 4,075
Cost of goods sold	1,276	772	2,989	1,826
Gross margin	1,819	952	4,184	2,249
Operating expenses:
Research and development	777	352	2,326	993
Depreciation and amortization	44	42	142	123
Selling, general and administrative	1,787	1,069	4,693	3,420
Change in fair value of contingent consideration	(94)		(113)
Total operating expenses	2,514	1,463	7,048	4,536
Loss from operations	(695)	(511)	(2,864)	(2,287)
Other income (expense):
Loss on extinguishment of debt				(199)
Interest expense	(48)	(32)	(140)	(146)
Interest income		1		3
Other expense, net	(1)	(8)	(31)	(32)
Net loss	(744)	(550)	(3,035)	(2,661)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(60)	(16)	(180)	(16)
Net loss attributable to Nephros, Inc. shareholders	$ (804)	$ (566)	$ (3,215)	$ (2,677)
Net loss per common share, basic and diluted	$ (0.10)	$ (0.08)	$ (0.43)	$ (0.4)
Weighted average common shares outstanding, basic and diluted	7,703,033	7,129,617	7,408,569	6,751,317
Comprehensive loss:
Net loss	$ (744)	$ (550)	$ (3,035)	$ (2,661)
Other comprehensive loss, foreign currency translation adjustments, net of tax	(7)	(1)	(8)	(4)
Comprehensive loss	(751)	(551)	(3,043)	(2,665)
Comprehensive loss attributable to noncontrolling interest	(60)	(16)	(180)	(16)
Comprehensive loss attributable to Nephros, Inc. shareholders	(811)	(567)	(3,223)	(2,681)
Product Revenues [Member]
Net revenues:
Total net revenues	3,054	1,648	7,067	3,822
Royalty and Other Revenues [Member]
Net revenues:
Total net revenues	$ 41	$ 76	$ 106	$ 253